Prediction of survival of diffuse large B‐cell lymphoma patients via the expression of three inflammatory genes

Abstract

Currently, several gene‐expression signatures that were used to predict survival of diffuse large B‐cell lymphoma (DLBCL) patients, showed a restriction on the practical work for lack of convenient operation. In this study, we screened inflammatory genes whose expression correlated with survival of DLBCL and established a predictive model including IL6, IL1A and CSF3 through multivariate Cox regression based on the expression of these three genes. We validated the model at protein level in our clinical serum cohort composed of 101 patients of DLBCL and 50 healthy controls and 534 DLBCL patients at mRNA level from three independent Gene Expression Omnibus (GEO) data sets. We found our model to be independent of the International Prognostic Index (IPI), moreover, it can augment the predictive power of IPI. In summary, our three‐gene model is sufficient to predict survival of DLBCL patients via measuring the concentration of three inflammatory cytokines in peripheral blood.

TBX21 predicts prognosis of patients and drives cancer stem cell maintenance via the TBX21–IL-4 pathway in lung adenocarcinoma

“…Li et al [ 10 ] reported that the inflammation-related gene IL-1β promotes stemness and invasiveness of colon tumor through activation of CSC self-renewal and EMT. Zhao et al [ 11 ] reported that a three inflammatory gene model including IL-6 , IL-1A and CSF3 could predict survival of diffuse large B-cell lymphoma patients, and patients with high-risk score of this signature had significantly shorter survival than those with low-risk score. The pathway analysis comprised of IRGs could determine genetic risk factors for cancers that might have an underappreciated modest inflammatory component.…”

Prediction of survival in non-Hodgkin lymphoma based on markers of systemic inflammation, anemia, hypercoagulability, dyslipidemia, and Eastern Cooperative Oncology Group performance status

“…Anemia reflects an unfavorable prognosis of tumor course [11,12]. According to the literature data, blood cytokine levels are important for predicting the survival of patients with hematological neoplasms, in particular, those with NHL [3,4]. This is due to the influence of cytokines on the proliferation, differentiation, and migration of tumor and stromal cells, as well as on the regulation of communication between a tumor and its stroma, and the interaction of a tumor with its extracellular matrix [15].…”

“…It should be noted that the relationship between levels of cytokines and survival is studied, as a rule, in patients with concrete mature lymphoid neoplasms, such as diffuse large B-cell lymphoma [3].…”

“…However, in patients with identical prognostic indexes, different disease courses are often observed [1]. On the other hand, we do not have universal prognostic factors for all types of NHL, although there are different data in the literature about new predictive markers in some concrete NHL cases [2,3]. It is known that systemic inflammation, hypercoagulability, and dyslipidemia play a vague role in pathogenesis, progression, and complications of NHL [4][5][6][7].…”

An Inflammation-Related Nine-Gene Signature to Improve Prognosis Prediction of Lung Adenocarcinoma

“…Functionally, PCDH7 silence inhibited ERK activation and tumor growths [ 14 ]. Zhao and his group observed that three inflammatory genes (CSF3, IL-1A, and IL-6) were associated with long-term survivals of patients with B-cell lymphoma [ 15 ]. To date, there are no researches regarding a prevailing model based on inflammation-related genes for the prediction of clinical survivals of LUAD patients.…”